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Abstract: Superoxide dismutases (SODs) are highly efficient
enzymes for superoxide dismutation and the first line of de-
fense against oxidative stress. These metalloproteins contain
a redox-active metal ion in their active site (Mn, Cu, Fe, Ni)
with a tightly controlled reduction potential found in a close
range around the optimal value of 0.36 V versus the normal
hydrogen electrode (NHE). Rationally designed proteins with
well-defined three-dimensional structures offer new oppor-
tunities for obtaining functional SOD mimics. Here, we ex-
plore four different copper-binding scaffolds: H3 (His3), H4
(His4), H2DH (His3Asp with two His and one Asp in the same
plane) and H3D (His3Asp with three His in the same plane)
by using the scaffold of the de novo protein GRa3D. EPR
and XAS analysis of the resulting copper complexes demon-
strates that they are good CuII-bound structural mimics of
Cu-only SODs. Furthermore, all the complexes exhibit SOD
activity, though three orders of magnitude slower than the
native enzyme, making them the first de novo copper SOD
mimics.
Introduction
Superoxide dismutases (SODs) are highly conserved metalloen-
zymes that have evolved to protect organisms from oxidative
stress.[1, 2] Four types of SODs have been identified, but only
three have been extensively studied (Table 1).[1, 3] The first well-
characterized class of SODs is the Fe/MnSOD, which can func-
tion with iron only, manganese only, or either metal in the
case of cambialistic enzymes. These proteins have high se-
quence identity and the same His3Asp metal-binding site re-
gardless of the active metal.[4] The second is the NiSOD, which
contains a His2Cys binding site.
[5] The third type of well-charac-
terized SODs are Cu/ZnSODs. General features of Cu/ZnSODs
include a Greek key b-barrel backbone, an electrostatic loop, a
disulfide bond, and a conserved active site.[1–3] In its reduced
state, the catalytic copper is bound by three histidines in a
trigonal plane. Upon oxidation, the CuII is bound in a distorted
square pyramid by an additional, bridging histidine and a
water molecule. The bridging histidine also binds to the struc-
tural zinc ion, which is further coordinated by two other histi-
dines and an aspartate.[1] Interestingly, a fourth class of SODs,
that is, Cu-only SODs, has recently been described containing
a single copper metal ion in the active site.[6–10] In these en-
zymes, the two histidines chelating the zinc ion in Cu/Zn SODs
are missing, either due to substitution or deletion. Thus, the
active site only contains four histidines capable of chelating
copper. All four His residues coordinate CuII in a pseudo-trigo-
nal pyramid, whereas CuI is coordinated by only three His resi-
dues in a pseudo-trigonal-planar arrangement with the fourth
His at a longer distance.[6] In C. albicans Cu-only SOD5, the role
of the zinc ion in promoting pH-independent catalysis is
adopted by a glutamate residue (Glu110) that interacts
through hydrogen bonding with the bridging histidine.[10]
Despite their differences in structure, active site, and metal
center, all SODs catalyze superoxide dismutation at diffusion-
Table 1. Summary of SODs activities.
SOD Activity [m@1s@1] pH
Fe[11] 3.25 V 109 7.8
Mn[11] 3.78 V 109 7.8
Ni[12] 1.3 V 109 7.0
Cu/Zn[6] 1.2 V 109 7.0
Cu only[6] 1.8 V 109 6.0
1.1 V 109 7.25
cyclodextran (Cu/Zn)[13] 9.90 V 107 7.8
N-term Cu/Zn model HADHDHKK[14] 2.7 V 107 7.0
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limited rates between pH 4 and 10.[1] Their reduction potentials
are tightly controlled and fall in a close range around the opti-
mal value of 0.36 V versus the normal hydrogen electrode
(NHE) at physiological pH, corresponding to the midpoint po-
tential between the oxidation (@0.18 V vs. NHE) and the reduc-
tion (+ 0.91 V26 vs. NHE) of superoxide.[1]
Low-molecular-weight complexes mimicking SODs with a
manganese, iron, or copper metal ion have been thoroughly
described in the literature.[2, 15–22] The challenges faced in their
design include stability, flexibility to adapt the coordination of
different metal redox states, and tuning the reduction poten-
tial to enable superoxide dismutation. For Cu/Zn SOD mimics,
cyclodextrin[13, 20] and bisdioxocyclan derivatives[23, 24] are among
the most efficient SOD mimics reported, with kcat values only
ten-fold lower than that of the native enzyme under similar
conditions. Peptidic Cu/Zn SOD mimics have also been stud-
ied,[14, 25–33] with the aim to reproduce the active site of the
enzyme by using short sequences of amino acids (three to ten
residues) that contain two to four histidine moieties. One of
the most active peptidic mimics of Cu/ZnSODs was reported
by ]rus et al.[14] These unstructured peptide sequences contain
three histidines (HADHDHKK) and bind copper in a 1:1 ratio. At
pH 7.0 its kcat value is 2.7 10
7 m@1 s@1, which is only two orders
of magnitude lower than that of the native Cu/Zn SOD. As
many of these peptidic models are mononuclear Cu catalysts,
they can provide some amount of insight into the Cu-only
SOD system, but no models of Cu-only SODs have previously
been described.
Widening possibilities beyond low-molecular-weight com-
plexes, rationally designed self-assembling peptidic scaffolds
with well-defined secondary and tertiary structures are tools of
choice to mimic the structure and activity of an enzyme.[34–42]
Only one manganese SOD mimic has been reported, which
uses this type of construct with modest SOD activity (kcat =
3.7 105 m@1 s@1 at pH 7.4).[43] By using protein redesign Benson
et al. have obtained a functional iron SOD mimic by introduc-
ing a His3 metal-binding site and a pocket for O2 binding into
E. coli thioredoxin (kcat = 6.4 10
6 m@1 s@1 at pH 8).[44, 45]
Herein, the GRa3D de novo protein scaffold was used to
design a functional mimic of Cu-only SODs. The a3D family of
proteins, originally designed by DeGrado et al. , consists of
seven amino acid repeats in which the first and fourth residue
of each heptad is hydrophobic.[36] In solution, these hydropho-
bic residues collapse to form the core of an antiparallel three-
helix bundle.[35, 46] Metal-binding residues can then be intro-
duced into this core to construct metalloproteins, though a
loss of stability is incurred.[47–49] This scaffold has previously
been used to study both electron-transfer proteins, such as cu-
predoxins and rubredoxins, and catalytic proteins, such as car-
bonic anhydrase.[47, 49–52] An elongated version of this peptide,
GRa3D, was designed with an additional heptad for improved
thermodynamic stability.[53] Four binding sites were introduced
into the protein; H3 (His3), H4 (His4), H2DH (His3Asp with two
His and one Asp in the same plane), and H3D (His3Asp with
three His in the same plane) (Table 2). The stability of the apo-
and CuII protein was studied by thermal denaturation and the
complexes were characterized by electron paramagnetic reso-
nance (EPR), extended X-ray absorption fine structure (EXAFS),
and cyclovoltammetry (CV) experiments. Their SOD activity
was assessed by the indirect assay of McCord–Fridovich.[54–56]
Results
Protein design
Four constructs were built within the GRa3D de novo protein
scaffold with varying active sites meant to recapitulate that of
two different classes of SODs, the is, Cu-only SODs and Fe/
MnSODs. Their sequences are listed in Table 2. Constructs with
an A98C mutation were used for electrochemical experiments.
The four different active sites designed within GRa3D for this
study are represented in Figure 1. GRa3D H3 contains three his-
Table 2. Designed protein amino acid sequences with mutations from GRa3D in bold and active site residues in blue. Electrochemical studies were per-






Figure 1. PyMol models of the designed His3 (H3), His4 (H4), His2AspHis (H2DH), and His3Asp (H3D) active sites within GRa3D based on the crystal structure of
GRa3D (PDB: 6DS9).
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tidines that replace leucine or phenylalanine (L25H, F38H,
L88H) in positions analogous to the carbonic anhydrase mimic
a3DH3, which also models the Cu
I-binding site of Cu-only
SODs.[47] GRa3D H4 contains a fourth histidine in position 35
(L35H) to mimic the CuII-binding site of Cu-only SODs.[6, 7] Con-
structs in which the fourth His residue was substituted by an
Asp were created to test the effects of modulating the reduc-
tion potential of the bound Cu. To this end, GRa3D H2DH and
GRa3D H3D, in which the Asp is either positioned in the same
plane as two other His (L38D), or below a plane constituted by
the three His (L35D), respectively, were designed. These con-
structs also model the active site of Fe/MnSODs, providing in-
teresting insight into the selectivity and catalytic efficiency of
substituting copper into this system.
Thermal stability of the apo- and CuII proteins
CD spectra of the apoproteins were obtained to test whether
GRa3D could properly fold with four large hydrophilic metal-
binding residues mutated into the hydrophobic core (Figure S1
in the Supporting Information). The double minima bands at
l= 208 and 222 nm are representative for an a-helical secon-
dary structure and indicate a well-folded three-helical bundle
peptide.[57, 58] We next sought to compare the destabilization
effects of the differing active sites. Thermal denaturation of
apo- and CuII proteins were studied and compared to that of
GRa3D by following the ellipticity of the proteins at l= 222 nm
at varying temperatures. The midpoint of unfolding (TM) was
determined by fitting the data to a two-state unfolding model
by using the program CDpal.[58–60] These values are summarized
in Table 3.
GRa3D is structurally stable in the temperature range used
with a melting temperature above 95 8C, which precludes cal-
culating the aforementioned thermodynamic parameters.
Three of the four constructs reported within this study, howev-
er, have melting temperatures below 95 8C, allowing for their
direct measurement. Comparing these four constructs, we find
that addition of a fourth residue destabilizes the protein as the
TM decreases over 10 8C between GRa3D H3 (TM>95 8C), and
GRa3D H2DH, H3D, and H4 (TM &80 8C). CuII-bound peptide is
thermodynamically more stable than the apopeptide, with TM
increasing by 5 to 10 8C depending on the construct. Overall,
the data assess that the apoproteins and the CuII complexes
are well folded at room temperature.
Interestingly, GRa3D H4 shows two steps in the unfolding
process in both the apo- and CuII-bound form (Figure 2). The
Table 3. Thermodynamic parameters of unfolding for apo- and CuII-
GRa3D three-helix bundles determined by thermal denaturation.
Peptide Apo peptide TM [8C] Cu peptide TM [8C]
GRa3D >95 –
GRa3D H2DH 79.8:0.7 85.1:0.9
GRa3D H3D 80.6:0.6 88:6
GRa3D H3 >95 >95
GRa3D H4 83.21:0.01 93.8:0.5
Figure 2. Thermal denaturation circular dichroism fits of GRa3D H3D, H2DH,
H3, and H4 (top to bottom). The spectra of the apoproteins are shown with
black circles and the ones of the CuII-bound species with red squares. Only
the second denaturation step was fit for GRa3D H4.
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first transition to an intermediate state occurs at 55 8C. The
second step occurs between 70 and 90 8C, similar to the other
constructs. Upon cooling, the first state is no longer observed
and reheating a sample results in a similar denaturation profile
to the renaturation profile (Figure S2 in the Supporting Infor-
mation).
CuII protein XAS and EPR characterization
X-ray absorption spectroscopy (XAS), consisting of both X-ray
absorption near-edge structure (XANES) and extended X-ray
absorption fine-structure (EXAFS), was done on CuII-GRa3D H3,
CuII-GRa3D H4, Cu
II-GRa3D H2DH, and Cu
II-GRa3D H3D and ana-
lyzed to investigate the structural differences between these
four SOD mimics (Figure 3). The average nearest-neighbor
bond lengths was between 1.94 and 1.95 a for all constructs
analyzed, consistent with 4-coordinate N- or O-bound CuII
(Table 4).
All constructs exhibit long distance backscatterers, which
best fit to three His ligands. All fits attempted are included
within the Supporting Information. This apparent similarity be-
tween the structure of the four constructs also extended to
XANES analysis, where the 1s!3d transitions (peak at 8979 eV)
for all four constructs were of similar height indicating an
equivalent degree of tetrahedral character to their geome-
try.[61, 62]
EPR spectra of the CuII proteins were collected in 50 mm 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer, pH 7.5 at 100 K with a 2:1 protein/CuII ratio to ensure
that all copper is bound (Figure 4). The g values and hyperfine
coupling constants of the CuII complexes were determined by
fitting with the SpinCount software and are listed in Table 5.[63]
Each complex has anisotropic g values with gx,gy<gz character-
istic of a dx2@y2 single-occupied molecular orbital (SOMO).
[64] To-
gether with the EXAFS data, the results suggest 4-coordinate
copper complexes in a distorted square-planar geometry.[64]
Two distinct species (A and B in Table 5) are observed in the
EPR spectra of CuII-GRa3D H3 and Cu
II-GRa3D H4. Simulation of
the EPR spectrum of GRa3D H3 shows that form A is dominant
and accounts for 75 % of the signal observed, whereas form B
accounts for 25 %. For GRa3D H4 the two species are present
in the same ratio. The EPR parameters of a Cu-only SOD found
Figure 3. 1s!3d region of the CuII protein XANES spectra at pH 7.5 for
every construct reported.
Table 4. CuII EXAFS and XANES fitting parameters at pH 7.5.
Construct Model Cu@O/N* R [a] Cu@O/N* s2 [10@3 a2] Cu@imid R [a] Cu@imid s2 [10@3 a2] Avg. bond length [a] 1s!3d area
GRa3D H3 His3O1 1.966 5.7 1.935 13.28 1.943 8.27
GRa3D H4 His3N1 1.881 4.4 1.972 6.23 1.949 6.89
GRa3D H2DH His3O1 1.981 1.5 1.933 8.06 1.945 5.41
GRa3D H3D His3O1 1.989 2.0 1.933 7.86 1.947 3.09
Figure 4. Electronparamagnetic resonance spectra of the constructs present-
ed in this study recorded at pH 7.5. Fits were done by using the program
SpinCount.
Table 5. EPR parameters obtained from simulation of EPR spectra of CuII
protein solutions.
gx gy gz Ajj [10
@4 cm@1] f = gz/Ajj [cm]
GRa3D H3
[a] 75 % A 2.05 2.04 2.27 166 136.8
25 % B 2.05 2.03 2.22 149 149.0
GRa3D H4
[a] 50 % A 2.012 2.04 2.26 158 143.0
50 % B 2.04 2.03 2.23 188 119.6
GRa3D H2DH
[a] N/A 2.06 2.03 2.27 162 140.2
GRa3D H3D
[a] N/A 2.04 2.04 2.26 168 134.5
Cu only SOD[b] N/A 2.05 2.05 2.26 &140 161.4
Cu-(Fe) SOD[c] N/A 2.05 2.05 2.37 136 174.3
[a] X-band EPR spectra recorded at 100 K on solutions of 1 mm CuCl2 and
2 mm protein in 50 mm HEPES buffer containing 30 % glycerol at pH 7.5,
9.3 GHz, 20.5 mW, 1 G. [b] Reference [7] . X-band EPR spectra of a Cu-only
SOD from Mycobacterium tuberculosis. [c] Reference [70]. X-band EPR
spectra recorded at 10 K of a copper-substituted Fe SOD from the archae-
on Acidianus ambivalens in Tris/HCl buffer at pH 7, 9.6452 GHz, 20 mW,
and 10.0 G.
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in Mycobacterium tuberculosis (His4 active site) and a copper-
substituted FeSOD from the archaeon Acidianus ambivalens
(His2AspHis) are given in Table 5.[7, 65] The CuII-GR 3D derivatives
have g values similar to these native enzymes and slightly
higher Ajj values.
One may also attempt to correlate the hyperfine coupling
constant observed in EPR to variation in activity between the
constructs reported. The empirical factor f = gz/Ajj correlates
with tetrahedral distortions where values between 105 to
135 cm are indicative of square-planar geometry and higher
values indicate distortion towards tetrahedral structures.[66, 67]
According to the values in Table 5, our constructs are more tet-
ragonal than the native examples, which may be correlated to
the decreased activity compared to the native enzymes. This is
bolstered by the case of GRa3D H4 in which two species are
evident at a 1:1 ratio. The GRa3D H4 species B has an f factor
of 119.6 cm, indicating that this species is more tetragonal
than GRa3D H4 species A with an f factor of 143.0 cm or any
other construct reported in this manuscript. The activity of
GRa3D H4 is also about half that of any of the other de novo
constructs, which could be explained by species B being an in-
active form. However, the differences in activity observed are
too minor to make definitive claims about the requirement of
tetrahedral distortion for the activity of CuSODs. Future studies
with other designed proteins may allow to elucidate this rela-
tionship more clearly.
CuI protein XANES characterization
The XANES region of all four constructs were analyzed to in-
vestigate the coordination geometry. The CuI 1s!4p transition
at 8982–8985 eV was analyzed to determine geometry differ-
ences between the constructs. The intensity of this peak is in-
dicative of the coordination number with higher peak intensi-
ties correlating with lower coordination number.[68] GRa3D H3D
has the lowest 1s!4p transition signal, indicative of a higher
coordination number (Figure 5). GRa3D H3 and GRa3D H4 have
similar intermediate transition signals. GRa3D H2DH has the
highest transition signal, indicative of a lower coordination
number, likely more 2-coordinate than 3-coordinate.
Reduction potentials, affinity, and SOD activity
The apparent standard potentials of CuII complexes containing
a C-terminal Cys (Ala98Cys) and grafted on a gold electrode
are listed in Table 6 with the cyclic voltammograms given in
Figure S3 in the Supporting Information. All four constructs
share # similar first-coordination sphere His3N/O around the
metal center as demonstrated by EXAFS analysis, however, the
potential of GRa3D H3 is notably higher than that of the other
three at 550 mV versus NHE compared to 420–470 mV versus
NHE. The reduction potentials of the four constructs lie in be-
tween the potentials for oxidation of superoxide to peroxide
(@0.18 V vs. NHE) and the reduction of superoxide to dioxygen
(+ 0.91 V vs. NHE), which should enable catalysis of superoxide
dismutation.
The CuII affinities for each of these four constructs were de-
termined in an effort to account for these differences in the re-
duction potential (Table 6). Interestingly, though GRa3D H3 has
a much higher reduction potential, it does not have a CuII af-
finity that is significantly different from that of GRa3D H2DH
and GRa3D H3D. GRa3D H4 has the weakest Cu
II affinity with a
Kd of 5.7 V 10
@10 m, indicating that a fourth His residue does not
play a significant role in the binding of CuII.
The calculated CuI affinities vary by two orders of magnitude
across the four constructs. CuI binds tightest to GRa3D H3, with
a Kd of 1.22 V 10
@16 m GRa3D H3D has an intermediate Cu
I affini-
ty (8.8 V 10@16 m), whereas both GRa3D H4 and H2DH have a
weaker affinity of 4.1 V 10@15 and 5.4 V 10@15 m, respectively
(Table 6). Thus, adding a fourth peptide ligand decreases the
CuI affinity of the protein but to different extents.
The SOD activities of the Cu proteins were measured by the
McCord–Fridovich (McF) assay,[54, 55] in which a secondary
probe, sodium 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tet-
razolium-5-carboxanilide (XTT), is used to determine the
amount of superoxide removed from solution by the SOD
mimic.[56] This assay is an indirect method to measure kcat, but
its reliability has been validated by direct methods (stopped-
Figure 5. 1s!4p region of the CuI protein XANES spectra at pH 7.5 for
every construct reported.
Table 6. Apparent standard potentials at pH 7.5, affinity constants, and














GRa3D H3 550:10 5.00:0.17 1.22:0.04 2.9:0.6 3.0:0.6
GRa3D H4 463:10 5.7:0.3 41:2 8.0:1.7 1.1:0.2
GRa3D H2DH 420:10 1.4:0.4 54:15 3.5:1.1 2.6:0.8
GRa3D H3D 470:10 1.6:0.2 8.8:1.1 3.3:0.3 2.6:0.2
[a] The CuII proteins bearing a GSGC tail were grafted on an Au electrode
and CV spectra were recorded at v = 0.05 V s@1 in an electrochemical
working cell containing 50 mm HEPES buffer, pH 7.5 at room tempera-
ture. Counter electrode (CE): Pt wire, reference electrode: standard calo-
mel electrode (SCE). [b] IC50 (mm) and kMcF (10
6 m@1s@1) values were deter-
mined from triplicate experiments with CuII proteins (4:1 ligand/metal (L/
M)) in 50 mm HEPES buffer, pH 7.5 with 100 mm XTT, 200 mm xanthine,
and xanthine oxidase at 25 8C. kXTT = 8.6 10
4 m@1s@1 (in phosphate-buffered
saline (PBS) 50 mm, pH 7.8). Note that the rate reported for GRa3D H3 is a
composite of two species as observed by EPR spectroscopy.
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flow and pulse radiolysis).[69–73] The assay was performed by
using an excess of ligand (4:1 protein/CuII) to ensure no free
copper is present. The IC50 is the concentration of SOD mimics
at which 50 % of the superoxide produced are dismutated by
the SOD mimics. From this value, the kMcF, which can be com-
pared to a catalytic rate constant, is calculated
(Table 6).[2, 54, 55, 69–72] GRa3D H3, GRa3D H2DH, and GRa3D H3D
have similar IC50 (2.9–3.5 mm) and kMcF (3 10
6 m@1 s@1) values,
whereas GRa3D H4 has a lower SOD activity with the highest
IC50 (8.0 mm) and lowest kMcF (1.1 10
6 m@1 s@1). The apoproteins
showed no SOD activity in the same concentration range. Ad-
ditional controls were performed to check that no reaction
occurs between the complex and formazan, and that the com-
plex did not inhibit xanthine oxidase.
Discussion
The Cu-only SOD models presented here demonstrate that an
exact reproduction of the active site is not necessary for
modest SOD activity, but that the native residues play an im-
portant role in mediating this activity. Previous work with Cu/
Zn SODs has shown that loss of even a single histidine in the
active site results in a loss of SOD activity, typically through a
loss of copper binding.[74–76] Although similar work on Cu-only
SODs has not been performed, the present work suggests that
all four histidine residues are not necessary for copper binding
or SOD activity.
Studies of the CuII-bound forms indicate that all four models
are structurally similar to Cu-only SODs. EPR experiments show
that all four constructs are similar to both CuII-bound Cu-only
SODs and CuII-substituted FeSODs.[7, 65] The fourth protein
ligand is not vital in modulating the structure of the CuII-bind-
ing environment as observed by EPR spectroscopy but does
determine how many species are present in solution. Both con-
structs with an Asp ligand contain a single species, whereas a
fourth His ligand or lack of a fourth protein ligand results in
two species. This is confirmed by CD for GRa3D H4 as two un-
folding steps are observed. Of these two species, only the
more stable is observed upon cooling the sample. The fourth
ligand, therefore, is necessary to restrict CuII binding to only a
single confirmation. A fourth aspartate ligand, regardless of
the position, may both coordinate the copper and orient a his-
tidine residue in a single geometry. In both Cu/Zn and Cu-only
SODs, an aspartate ligand orients the histidine residue that is
bound only in the CuII form and loss of this residue results in a
decrease of the SOD activity.[10, 77] The second species present
may simply be a result of different histidine coordination in
these systems.
This is corroborated by the XAS data. Although these experi-
ments cannot distinguish between multiple coordination
states, the average indicates that all three histidines are bound
in all four constructs. The fourth residue is likely an additional
histidine in GRa3D H4 or an oxygen in the remaining three con-
structs. This oxygen may be from either the Asp ligand that is
present in GRa3D H3D or H2DH or a solvent residue. Thus, the
Asp may be binding the copper as a fourth residue or the CuII
coordination sphere is completed by water and the Asp solely
acts to orient a histidine residue.
The CuII affinity is also affected by this fourth ligand. GRa3D
H4 has the weakest Cu
II affinity, though only slightly weaker
than GRa3D H3. If, however, the fourth ligand is an Asp residue
instead, the CuII affinity increases by a factor of three. The posi-
tion of this Asp residue does not have a significant effect on
the affinity of the cupric ion. This indicates that a fourth
oxygen ligand lends to tighter CuII binding than an imidazole
ligand.
The fourth ligand is also important in modulating the
copper reduction potential. Though all four constructs are cat-
alytically active, GRa3D H3 has a much higher reduction poten-
tial than the constructs with a fourth amino acid ligand. Simply
adding a fourth ligand decreases the midpoint potential by
80–130 mV, depending on the construct. This may be by re-
moving solvent from the active site or by limiting the amount
of rearrangement necessary to convert between the CuI- and
CuII-bound forms.[78] None of the constructs is close to the de-
sired 360 mV versus NHE, the midpoint between the reduction
and oxidation of superoxide.[2, 3] Disrupting the His3 plane de-
creases the reduction potential by 50 mV from approximately
470 to 420 mV versus NHE, even though the CuII affinity re-
mains unchanged between GRa3D H3D and H2DH. The rear-
rangement of the Asp residue does more to stabilize the CuII-
bound enzyme outside of increasing the affinity for CuII. The
axial His in GRa3D H2DH is positioned in a more open, solvent-
exposed cavity, which may allow for easier conversion between
the CuI and CuII forms than in GRa3D H3D. In that construct the
three histidines are located in a more spatially confined posi-
tion within the peptide preventing such easy rearrangement.
Calculated CuI affinities also provide insight into the copper-
binding environment. Unsurprisingly given the relatively weak
CuII affinity and high reduction potential, GRa3D H3 has the
tightest CuI affinity. GRa3D H2DH has the weakest Cu
I affinity,
correlated with the low reduction potential and has the most
two-coordinate character measured by XANES. Again, the iden-
tity and placement of the fourth ligand significantly affects
cuprous binding. The identity of the axial ligand may account
for this difference. With no axial peptide ligand (GRa3D H3), Cu
I
binds with the highest affinity. In the CuII-bound form, the co-
ordination sphere is completed with an axial solvent residue.
This is most similar to GRa3D H3D, containing an axial Asp resi-
due in addition to the His3 plane, which results in an 8-fold
loss in the CuI affinity. Maintaining the His3 plane and adding
an axial His residue (GRa3D H4) further decreases the Cu
I affini-
ty (40 V weaker than GRa3D H3). Disruption of the His3 plane
results in the greatest loss of CuI affinity and corresponds to
the lowest reduction potential and highest CuII affinity. Clearly,
GRa3D H2DH most favors the oxidized species.
All four constructs exhibit measurable SOD activity, though
still three orders of magnitude slower than the native enzyme.
They are more efficient than the previously reported manga-
nese de novo mimic (kMcF = 3.7 10
5 m@1 s@1), and have a similar
activity to the iron SOD mimic reported by Benson et al. (kcat
6.4 106 m@1 s@1).[43–45] The slowest construct, GRa3D H4, also has
the weakest overall copper affinity, which is known to decrease
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activity.[74–76] The remaining three constructs are 2.5–3-times
faster but do not have statistically different rates. Thus, the
trends in CuI/II affinity and reduction potential do not corre-
spond to trends in SOD activity. Previously, trends in reduction
potential and SOD activity were observed for low-molecular-
weight manganese SOD mimics, which show a better SOD ac-
tivity when the reduction potential is closer to 0.36 V versus
NHE, the midpoint potential between the oxidation and reduc-
tion of superoxide.[1–3, 18, 19, 21] This observation applies for other
copper SOD mimics.[1–3, 18, 19, 20]
At this point, we are unable to determine if these peptides
are rate-limited by product release or conversion between the
oxidized and reduced metal species. There may be a measura-
ble difference in substrate conversion among the three more
active peptides following the reduction potential trend that is
unobservable due to slow product release.
To conclude, this study is the first example of the design of
functional Cu-only SOD mimics in de novo proteins and shows
that all four His residues from the native active site are not re-
quired for SOD activity within a de novo construct. The activity
of these constructs is much slower than that of the native
enzyme and further studies will be done to address this. The
CuI environment and dynamics between the CuI- and CuII-
bound species will be characterized to provide insight into this
difference. These states could provide insight into the rate of
catalysis and may highlight the importance of the fourth
copper ligand. By modifying this fourth ligand, both in ligand
type and position, we aim to improve the rate of catalysis and
determine the most efficient coordination environment for
SOD activity in de novo protein models.
Experimental Section
Protein expression and purification : pET15B recombinant DNA
plasmids (Celtek Genes) containing the gene for the GRa3D con-
structs were transformed and expressed in E. coli BL21(DE3) com-
petent cells (Life Technologies). The Ala98Cys derivatives of the
GRa3D constructs were prepared for electrochemical studies.
Colonies were inoculated in lysogeny broth (LB) medium (30 mL)
and ampicillin (100 mg mL@1) before being incubated at 37 8C and
175 rpm for 6–7 h. Autoinduction medium was inoculated with
10 mL/1 L culture flask at 25 8C and 250 rpm for 18 h to overex-
press the proteins. Cells were pelleted, resuspended in 1.0 mm
phosphate buffer saline solution containing 2 mm dithiothreitol
and 2 mm ethylenediaminetetraacetic acid (EDTA) and lysed with a
microfluidizer. The soluble protein was isolated after heat denatu-
ration at 55 8C and acidification to pH 2 to remove contaminant
proteins. The supernatant was filtered through a syringe (0.2 mm)
and purified on a reversed-phase C18 HPLC by using a flow rate of
20 mL min@1 and a linear gradient of 0.1 % trifluoroacetic acid (TFA)
in 3:7 CH3CN/H2O to 0.1 % TFA in 7:3 CH3CN/H2O over 35 min. The
molecular weight of the purified peptide was confirmed by ESI-MS
(collected on a Micromass LCT Time-of-Flight Mass Spectrometer)
and found to correspond to the expected protein mass after dele-
tion of the N-terminal methionine residue. Protein concentrations
were determined by measuring the absorbance with e280 =
8480 m@1 cm@1.
Circular dichroism (CD) spectroscopy
CD spectra were collected on a Jasco J-1500 CD spectropolarimeter
at 25 8C by using 1 cm path length quartz cuvettes. Samples con-
tained 10 mm phosphate buffer, pH 7.0, and 10 mm protein. CuII-
containing samples also included 11 mm CuCl2. Thermal denatura-
tion samples were heated at 5 8C min@1 and the ellipticity was re-
corded every 5 8C from 25 to 100 degrees after stabilization within
:0.1 8C of the desired temperature and an additional equilibration
time of five minutes. Molar ellipticities ([q]) were calculated by
using previously reported procedures.[58, 79, 80]
CuII-binding affinity
The binding affinity of CuII to each peptide was determined by
using the competitive chelator 3,4-bis(oxamato)benzoic acid
(baba). Solutions containing 50 mm peptide and 45 mm CuCl2 in
50 mm HEPES pH 7.5 were titrated with 0.1 equivalents of baba
with ten minutes of equilibration time between additions. The re-
verse titration was also performed with 50 mm baba and 45 mm
CuCl2 in 50 mm HEPES pH 7.5. The absorbance of the Cu
II–baba
complex was monitored at l= 330 nm and fit by using previously
described methods.[81]
CuI binding affinity
The binding affinity of CuI was calculated at pH 7.5 based on the
CuII-binding affinity and the reduction potentials of each peptide
[Eq. 1] . A value of 0.159 V versus NHE was used for E8ðCuII=I ,aqÞ.
[82, 83]







Where R = 8.314 J mol@1 K@1, n = number of electrons, and F =
9.648 V 104 C mol@1.
X-ray absorption spectroscopy
CuII samples were prepared with 1.0 mm CuII acetate and 1.5 mm
peptide in 0 mm HEPES buffer at pH 7.5 in aerobic conditions.
Samples were then lyophilized before transferring to sample cells
as a dried powder. The Cu edge energy and 1s!4p transition of
the CuI peptide were monitored and it was estimated that no
more than 10 % of the sample was photoreduced in the scans in-
cluded in fits.
CuI samples were prepared with 1.0 mm tetrakis(acetonitrile)CuI
hexafluorophosphate and 1.5 mm peptide in 50 mm HEPES buffer
at pH 7.5 in anaerobic conditions. 50 % glycerol were added to the
solution as a glassing agent before sample solutions were loaded
into an XAS sample cell and frozen in liquid nitrogen.
Measurements were carried out at Stanford Synchrotron Radiation
Lightsource (SSRL) beamline 7-3 or 9-3 with a Si(220) double-crystal
monochromator and a flat Rh-coated harmonic rejection mirror.
Samples were maintained below 10 K with an Oxford Instruments
liquid helium cryostat. Data were measured as fluorescence excita-
tion spectra by using a 30- or 100-element Ge detector array (for
beamlines 7-3 or 9-3, respectively) normalized to incident intensity
measured with a N2-filled ion chamber. Data were measured with
steps of 0.25 eV in the XANES region (1 s integration time) and
0.05 a@1 in the EXAFS region to k = 13.5 a@1 (1&20 s integration,
k3-weighted). Energies were calibrated by assigning the lowest-
energy inflection point of a copper metal foil as 8980.3 eV. An ini-
tial E0 value of 9000 eV was used to convert data to k-space, and
the background was removed by using a 3-region cubic spline.
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EXAFS data were analyzed by using EXAFSPAK[84] and FEFF 9.0.[85]
XANES data were normalized by using MBACK.[86] For analysis of
the 1s!3d transitions, data were fitted with an arctan background
with a pseudo-Voigt peak to model the rising edge and the 1s!
3d peak, and this fitted background was then subtracted from the
data. CuI spectra were analyzed in this way to determine the
degree of oxidation of XAS samples. The absence of any peak
above the noise in these spectra indicate that oxidation was mini-
mal.
Single- and multiple-scattering fitting of EXAFS data were per-
formed by using EXAFSPAK[84] with ab initio amplitude and phase
parameters calculated by using FEFF 9.0.[85] An initial model of Cu–
imidazole coordination was built based on the averaged bond
lengths determined by single-scattering fitting of the EXAFS data.
An initial model of Cu–imidazole coordination was built based on
the average Cu@N bond lengths determined by single-scattering
fitting of the EXAFS data, with the imidazole bond-lengths and
angles taken as the average of all Cu–imidazole structures con-
tained in the Cambridge Structural Database. All significant non-
hydrogen paths, defined as those having an amplitude greater
than 4 % of the Cu@N amplitude, from this model were then
loaded into EXAFSPAK and modeled as a rigid ligand. Initial esti-
mates of the Debye–Waller factors for each Cu–imidazole shell
were taken from calculations by Dimakis and Bunker.[87] The Cu@N
bond length and Debye–Waller factor were allowed to vary, with
the length and Debye–Waller factor for the other paths calculated
based on the Cu@N values. Thus, the long distance scattering from
the Cu–imid was modeled while only varying two independent
variables.
Electron paramagnetic resonance (EPR) spectroscopy
X-band EPR spectra were collected on a Bruker EMX electron spin
resonance spectrometer with a Varian liquid nitrogen cryostat at
100 K. EPR samples contained 1 mm CuIICl2, 1.5–2 mm peptide,
50 mm HEPES pH 7.4, and 30 % glycerol. Each sample was flash-
frozen in liquid N2 before measurement. To obtain Cu
II EPR parame-
ters, each spectrum was simulated on SpinCount.[63]
Electrochemistry
Cyclic voltammetry measurements were obtained on a Metrohm
AUTOLAB potentiostat (PGSTAT302N).
The electrochemical apparatus contained a gold (Au) disk working
electrode (1 mm diameter), a platinum wire counter electrode, and
an aqueous saturated calomel electrode (SCE) as the reference
electrode (0.241 V + SCE = normal hydrogen electrode). The gold
surface was polished with diamond slurries having decreasing par-
ticle sizes in the following order: 6-3-1 mm. Au electrodes were
conditioned in an electrochemical cell containing 0.5 m H2SO4, by
scanning from @300 to + 1500 mV vs. SCE at 500 mV s@1 until the
cyclic voltammograms overlaid to indicate a homogeneous surface.
After each electrode had been polished and conditioned, 50 mL of
a 0.5 mm CuII–protein Ala98Cys solution in 50 mm HEPES buffer
pH 7.5 were chemically adsorbed on the Au surface for 2–3 h. CVs
were collected in 50 mm HEPES buffer, pH 7.5 at varying scan rates
at room temperature (22–28 8C).
SOD activity
The SOD activity of the copper complexes was determined by
using the indirect assay of McCord–Fridovich observing XTT reduc-
tion.[54–56] Superoxide anions were generated by a xanthine– ox-
idase system and detected by monitoring the formation of forma-
zan at l= 470 nm. The reactions were performed in 50 mm HEPES
buffer pH 7.4 with 100 mm XTT and 200 mm xanthine. An appropri-
ate amount of xanthine oxidase was added to start the reaction
and generate a change in absorbance of 0.025–0.030 min@1. The
absorbance at l= 470 nm was monitored for 1.5 min (slope P1)
before addition of the SOD mimic, and for another 1.5 min after
addition (slope P2). A plot of the ratio (P1@P2)/P1 as a function of
SOD mimic concentration was used to calculate the inhibition con-
centration (IC50) at which the reduction of XTT to formazan is inhib-
ited by 50 % (P2 = 1=2 P1). A pseudo-catalytic rate constant, kMcF, was
deduced from the IC50 value by using the relation: kXTT V [XTT] =
(kMcF)(IC50), with kXTT = 5.94 V 10
4 m@1 s@1 (pH 7.8).[2] In order to ensure
that no free copper was present in solution the experiments were
performed with an excess of protein (4:1 protein/metal). The meas-
urements were performed in triplicate for each compound. Con-
trols with the apoproteins showed no SOD activity. Controls were
performed to determine that no inhibition of the xanthine–xan-
thine oxidase system resulted from the addition of the peptides.
The rate of conversion of xanthine to urate was monitored at l=
290 nm in the presence and absence of peptide and no inhibition
was observed. Possible formazan complexation was monitored at
l= 490 nm after addition of peptide and no decrease in absorb-
ance was detected, indicating no inhibition.[73, 88, 89]
Acknowledgements
V.P. , K.K. , and A.T. thank NIH grant R01 ES012236 for funding
and A.T additionally acknowledges the Chateabriand Fellow-
ship for funding. C.P. and E.M. acknowledge the network
FrenchBIC (http://frenchbic.cnrs.fr/) for E.M.’s fellowship for her
stay at Michigan. They also wish to thank ANR (ANR-15-CE07-
0027) and Fondation pour la recherche m8dicale
(DIE20151234413) for funding. O.I. acknowledges the financial
support from FundaÅ¼o para a CiÞncia e a Tecnologia [PTDC/
QUI-BIQ/098406/2008) and the Marie Curie Actions (FP7-
PEOPLE-IRG-230896).
Conflict of interest
The authors declare no conflict of interest.
Keywords: bioinorganic chemistry · enzymes ·
metalloenzymes · metalloproteins · protein design
[1] Y. Sheng, I. A. Abreu, D. E. Cabelli, M. J. Maroney, A.-F. Miller, M. Teixeira,
J. S. Valentine, Chem. Rev. 2014, 114, 3854 – 3918.
[2] C. Policar in Redox Active Therapeutics (Eds. : J. S. Reboucas, I. Batinic-
Haberle, I. Spasojevic, D. S. Warner, D. St. Clair), Springer, Cham, 2016,
pp. 125 – 164.
[3] I. A. Abreu, D. E. Cabelli, Biochim. Biophys. Acta Proteins Proteomics
2010, 1804, 263 – 274.
[4] J. D. Aguirre, V. C. Culotta, J. Biol. Chem. 2012, 287, 13541 – 13548.
[5] D. P. Barondeau, C. J. Kassmann, C. K. Bruns, J. A. Tainer, E. D. Getzoff,
Biochemistry 2004, 43, 8038 – 8047.
[6] J. E. Gleason, A. Galaleldeen, R. L. Peterson, A. B. Taylor, S. P. Holloway, J.
Waninger-Saroni, B. P. Cormack, D. E. Cabelli, P. J. Hart, V. C. Culotta,
Proc. Natl. Acad. Sci. USA 2014, 111, 5866 – 5871.
[7] L. Spagnolo, I. Tçrç, M. D’Orazio, P. O’Neill, J. Z. Pedersen, O. Carugo, G.
Rotilio, A. Battistoni, K. Djinović-Carugo, J. Biol. Chem. 2004, 279,
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